After Hours Top Loser 05 Feb 2026: GNCA Genocea NASDAQ at $0.0001, see liquidity

We saw GNCA stock plunge in after-hours trade on 05 Feb 2026, finishing at $0.0001 on NASDAQ in the United States after a -97.44% one-day move. This drop follows a thin intraday print, volume 30,268 shares, and a wide gap from the 50-day average price of $0.00 (reported $0.0047). GNCA Genocea Biosciences, Inc. remains a small-cap healthcare play with Chapter 11 proceedings in its history, and the market is pricing severe liquidity and execution risk into the shares.

GNCA stock price action and after-hours trading

GNCA stock closed after hours at $0.0001, down 97.44% versus the previous close of $0.0039. Trading shows 30,268 shares on the session against an average volume of 80,568, underlining low liquidity and a large bid-ask sensitivity.

The intraday range was $0.0001 to $0.0001, and the 52-week range is $0.0001 to $1.45, showing extreme compression from last year’s highs.

Balance sheet and key financial metrics for GNCA stock

Genocea reports cash per share $0.54 and book value per share $0.39, with a current ratio of 2.24, indicating short-term liquidity cushions on the books. The company shows negative earnings metrics: net income per share -0.22 and operating cash flow per share -0.66, reflecting ongoing cash burn.

Price multiples are effectively non-applicable: market cap prints 0 in the data set and price/earnings is None. Investors should treat valuation ratios with caution given the tiny quoted price and reporting gaps.

Clinical program updates and GNCA news impact

Genocea’s pipeline historically focused on neoantigen cancer immunotherapies including GEN-009 and GEN-011, both in Phase 1/2a stages. Chapter 11 filing in July 2022 remains a material event that explains part of the extreme share decline and investor skepticism.

No recent positive clinical readouts are reflected in market-moving news; the absence of catalyst increases downside risk for GNCA stock as traders detach from speculative clinical value.

Trading technicals, volatility and liquidity for GNCA stock

Short-term technicals show extreme weakness: price averaging metrics are 50-day $0.00472 and 200-day $0.11462, indicating a long trend down. Relative volume 0.38 signals low participation and high slippage risk for orders above small sizes.

Volatility metrics and trading spreads will be wide; retail and institutional execution costs likely overwhelm any speculative move without a formal corporate event.

Meyka AI grade and GNCA analysis

Meyka AI rates GNCA with a score out of 100: 58.59 | Grade C+ | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score reflects mixed balance-sheet cushions against severe revenue and operating losses.

This grade is informational only and not a guarantee. We are not financial advisors and advise readers to perform their own due diligence.

Risks and opportunities in GNCA stock outlook

Primary risks for GNCA stock are low liquidity, Chapter 11 legacy, and continued negative cash flows, which can push quoted price toward zero. Secondary risks include lack of analyst coverage and limited institutional interest.

Opportunities are limited to corporate restructuring, asset sales, or a surprise clinical or financing announcement that materially improves cash runway. Any positive catalyst would need to overcome investor skepticism and thin trading conditions.

Final Thoughts

Key takeaway: GNCA stock trades at $0.0001 on NASDAQ after hours on 05 Feb 2026, with a one-day decline of -97.44% and thin volume 30,268 shares. Meyka AI’s forecast model projects a near-term base case of $0.0001, a conservative recovery scenario of $0.0010 (implied upside +900.00%), and a recovery stretch target of $0.0200 (implied upside +19,900.00%). These scenario figures compare to the current price $0.0001 and reflect model-based projections, not guarantees. Given the company’s Chapter 11 history, zero market cap print, and weak operating cash flows, we view GNCA as highly speculative and primarily a trading, not investing, consideration. For real-time tracking and data-driven alerts, see our platform’s coverage at GNCA on Meyka. For recent market context, compare peer metrics at Investing.com GNCA compare and headline flow at MarketBeat GNCA mention. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.